Salix Pharmaceuticals manufacturers OsmoPrep, also known as the “The Tablet Prep” (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP).  Salix markets OsmoPrep as “the latest advancement in colonoscopy preparation” OsmoPrep was approved by the FDA in March 2006 for cleansing the colon in preparation for colonoscopy in adults over the age of 18.

OsmoPrep is advertised as being unique among bowel preps because it consists of a series of pills instead of a liquid prep and is taken with the clear liquid of the patient’s choice, allowing the patient to choose what the tablet will taste like  – not like an unpleasant liquid bowel prep.

On December 11, 2008 the U.S. Food and Drug Administration (FDA) announced that it was requiring the addition of a black box warning on oral sodium phosphate (OSP) products, including OsmoPrep regarding the potential to develop acute phosphate nephropathy. 

Contact an OsmoPrep Kidney Injury Lawyer about an Acute Phosphate Nephropathy Lawsuit Today

If you or a loved one used OsmoPrep or another OSP and suffered from acute phosphate nephropathy, contact an OSP Lawyer, Visicol Lawyer or Fleet Phospho Soda Lawyer today for a confidential free case evaluation.

Published November 17, 2011 by